Nanocapsules interacted with Dectin‐2 and TLR4 to induce TH17 cell differentiation, leading to decreased Tregs and increased TH17, CD8+ T cells, NK cells, and M1 macrophages in tumors, while OX40 blockade further boosted antitumor effects.[133] The mannan capsules loaded with ovalbumin (OVA)‐encoding mRNA led to significant bone marrow‐derived dendritic cell (BMDC) activation via Dectin‐2 and TLR‐4 to promote antigen presentation for the induction of strong antigen‐specific CD4+ and CD8+ T cell responses with robust anti‐tumor efficacy in a murine model of B16 cells expressing OVA.[263]. The gene discussed is TLR4; the disease is neoplasm.